The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: A case report

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Kishimoto, Akira ^a   Todani, Ayako ^b   Miura, Junko ^a   Kitagaki, Tetsuno ^a   Hashimoto, Kenji ^c  

^a National Hospital Organization   (Japan)

^b National Hospital Organization   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PEROSPIRONE; RISPERIDONE; SERTRALINE;

ADULT; ARTICLE; ATYPICAL DEPRESSION; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR DEPRESSION; OVERNUTRITION; PERSECUTORY DELUSION; PREMENSTRUAL SYNDROME; PSYCHOSIS; PSYCHOTIC MAJOR DEPRESSION;

EID: 77952461910     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-23     Document Type: Article

References (29)

1. Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry 2003, 64(Suppl 1):19-23.
2. Dannon PN, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Neurother 2006, 6:73-80. 10.1586/14737175.6.1.73, 16466314.
3. Hamoda HM, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression. Harv Rev Psychiatry 2008, 16:235-247. 10.1080/10673220802277904, 18661366.
4. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996, 153:414-416.
5. Zanardi R, Franchini L, Gasperini M, Smeraldi E, Perez J. Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol 1997, 12:195-197. 10.1097/00004850-199707000-00002, 9347379.
6. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000, 61:26-29.
7. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry 2009, 8:26. 10.1186/1744-859X-8-26, 2803775, 20025739.
8. Shirayama Y, Hashimoto K. A case of psychotic depression treated with fluvoxamine monotherapy. Clin Psychopharmacol Neurosci 2010, 8:53-54.
9. Simpson GM, El Sheshai A, Rady A, Kingsbury SJ, Fayek M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry 2003, 64:959-965. 10.4088/JCP.v64n0817, 12927014.
10. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005, 10:319-323.
11. Hayashi T, Su TP. Understanding the role of sigma-1 receptors in psychotic depression. Psychiatric Times 2005, 22:54-63.
12. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010, 3:25-36.
13. Søgaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, Ravindran AV, Reesal RT, Goodwin DP. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999, 13:406-414. 10.1177/026988119901300412, 10667618.
14. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998, 59:76-80.
15. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systemic review. Lancet 2000, 356:1131-1136. 10.1016/S0140-6736(00)02754-9, 11030291.
16. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pham Des 2006, 12:3857-3876.
17. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007, 131:596-610. 10.1016/j.cell.2007.08.036, 17981125.
18. Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009, 34:137-146.
19. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Sys Agents Med Chem 2009, 9:197-204.
20. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol Clin Exp 2010, 25:193-200.
21. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996, 307:117-119. 10.1016/0014-2999(96)00254-3, 8831113.
22. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007, 32:514-521. 10.1038/sj.npp.1301047, 16495935.
23. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 2008, 3:e2558. 10.1371/journal.pone.0002558, 2435603, 18596927.
24. Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu M, Minase T, Tanibuchi Y, Hagiwara H, Iyo M, Hashimoto K. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2009, 2:7-11.
25. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 2007, 62:878-883. 10.1016/j.biopsych.2007.04.001, 17662961.
26. Bellini L, Gasperini F, Gatti F, Franchini L, Smeraldi E. A double-blind study with fluvoxamine versus desipramine combined with placebo or haloperidol in delusional depression. Critical Issues in the Treatment of Affective Disorders 1994, Basel, Switzerland: Karger, Brunello N, Langer SZ, Mendlewicz J, Racagni G.
27. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996, 153:1631-1633.
28. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001, 50:345-50. 10.1016/S0006-3223(01)01145-3, 11543737.
29. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology. J Psychopharmacol 1998, 12(Suppl B):S5-S20.